253 related articles for article (PubMed ID: 22358188)
21. Immunosuppressive drug monitoring - what to use in clinical practice today to improve renal graft outcome.
Kuypers DR
Transpl Int; 2005 Feb; 18(2):140-50. PubMed ID: 15691265
[TBL] [Abstract][Full Text] [Related]
22. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporin C2hour monitoring after renal transplantation.
Einecke G; Mai I; Fritsche L; Slowinski T; Waiser J; Glander P; Böhler T; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):477-81. PubMed ID: 14703954
[TBL] [Abstract][Full Text] [Related]
24. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
Ware N; MacPhee IA
Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
[TBL] [Abstract][Full Text] [Related]
25. New strategies in immunosuppression.
Regazzi MB; Alessiani M; Rinaldi M
Transplant Proc; 2005; 37(6):2675-8. PubMed ID: 16182781
[TBL] [Abstract][Full Text] [Related]
26. New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients.
Sommerer C; Giese T; Meuer S; Zeier M
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1030-7. PubMed ID: 21060169
[TBL] [Abstract][Full Text] [Related]
27. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppressive strategies to improve outcomes of kidney transplantation.
Tang IY; Meier-Kriesche HU; Kaplan B
Semin Nephrol; 2007 Jul; 27(4):377-92. PubMed ID: 17616271
[TBL] [Abstract][Full Text] [Related]
29. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat.
Cramer DV; Chapman FA; Jaffee BD; Jones EA; Knoop M; Hreha-Eiras G; Makowka L
Transplantation; 1992 Feb; 53(2):303-8. PubMed ID: 1531394
[TBL] [Abstract][Full Text] [Related]
30. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection.
Nicholls AJ
Clin Biochem; 1998 Jul; 31(5):329-33. PubMed ID: 9721430
[No Abstract] [Full Text] [Related]
31. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.
Glander P; Sommerer C; Arns W; Ariatabar T; Kramer S; Vogel EM; Shipkova M; Fischer W; Zeier M; Budde K
Clin J Am Soc Nephrol; 2010 Mar; 5(3):503-11. PubMed ID: 20150450
[TBL] [Abstract][Full Text] [Related]
32. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
[TBL] [Abstract][Full Text] [Related]
33. [Therapeutic window of mycophenolate mofetil for preventing acute graft rejection following renal transplantation].
Yu L; Zhou M; Luo M
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Dec; 34(12):1842-5. PubMed ID: 25537916
[TBL] [Abstract][Full Text] [Related]
34. Current status of immunosuppressive minimization and tolerance strategies.
Brouard S; Budde K
Transpl Int; 2015 Aug; 28(8):889-90. PubMed ID: 26178312
[No Abstract] [Full Text] [Related]
35. Renal transplantation: can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings.
Gotti E; Perico N; Perna A; Gaspari F; Cattaneo D; Caruso R; Ferrari S; Stucchi N; Marchetti G; Abbate M; Remuzzi G
J Am Soc Nephrol; 2003 Mar; 14(3):755-66. PubMed ID: 12595513
[TBL] [Abstract][Full Text] [Related]
36. The impact of age on rejection in kidney transplantation.
de Fijter JW
Drugs Aging; 2005; 22(5):433-49. PubMed ID: 15903355
[TBL] [Abstract][Full Text] [Related]
37. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression.
Einecke G; Mai I; Fritsche L; Slowinski T; Waiser J; Neumayer HH; Budde K
Nephrol Dial Transplant; 2004 Jan; 19(1):215-22. PubMed ID: 14671060
[TBL] [Abstract][Full Text] [Related]
38. Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.
Kovarik JM
Drugs Today (Barc); 2004 Feb; 40(2):101-9. PubMed ID: 15045032
[TBL] [Abstract][Full Text] [Related]
39. Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.
Taylor E; Jones M; Hourigan MJ; Johnson DW; Gill DS; Isbel N; Hawley CM; Marlton P; Gandhi MK; Campbell SB; Mollee P
Nephrol Dial Transplant; 2015 Oct; 30(10):1774-9. PubMed ID: 26188340
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.
McCune JS; Bemer MJ
Clin Pharmacokinet; 2016 May; 55(5):525-50. PubMed ID: 26563168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
